DAMGO

• Description:

  DAMGO is a μ-opioid receptor (μ-OPR) selective agonist with a Kd of 3.46 nM for native μ-OPR[1].

• UNSPSC:

  12352209

• Target:

  Opioid Receptor

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/DAMGO.html

• Purity:

  99.87

• Solubility:

  DMSO : 33.33 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

• Smiles:

  OC1=CC=C(C[C@H](N)C(N[C@H](C)C(NCC(N(C)[C@H](C(NCCO)=O)CC2=CC=CC=C2)=O)=O)=O)C=C1

• Molecular Formula:

  C26H35N5O6

• Molecular Weight:

  513.59

• References & Citations:

  [1]FEBS Lett. 1995 Jan 2;357 (1) :93-7. Onogi T, et al. DAMGO, a mu-opioid receptor selective agonist, distinguishes between mu- and delta-opioid receptors around their first extracellular loops.|[2]Patel JP, et al. Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J Neurovirol. 2006 Dec;12 (6) :492-500.|[3]Gold MS, et al. DAMGO inhibits prostaglandin E2-induced potentiation of a TTX-resistant Na+ current in rat sensory neurons in vitro. Neurosci Lett. 1996 Jul 12;212 (2) :83-6.|[4]Desmeules JA, et al. Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain. Pain. 1993 Jun;53 (3) :277-285.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported

• Isoform:

  μ Opioid Receptor/MOR

• Citation 01:

  Alzheimers Res Ther. 2025 Feb 1;17 (1) :35.|Aquaculture. 2025 Apr 15.|bioRxiv. 2022 Jul 11.|bioRxiv. 2024 Jul 26:2024.07.26.605282.|Cell Rep Methods. 2025 May 19;5 (5) :101051.|Nature. 2025 Dec;648 (8094) :755-763.|Seoul National University. 2024 Feb.|Cell. 2022 Nov 10;185 (23) :4361-4375.e19.|Cell. 2023 Jan 19;186 (2) :413-427.e17.

• CAS Number:

  [78123-71-4]